Recombinant Bovine Growth Hormone vs Mineral Oil: which is worse?

What is Recombinant Bovine Growth Hormone?

Recombinant bovine growth hormone (rBGH), also called recombinant bovine somatotropin (rBST), is a synthetically produced version of the naturally occurring cattle growth hormone, manufactured using genetically engineered E. coli bacteria. Injected into dairy cows, it increases milk production by 10-15%. It was FDA-approved in 1993 under the brand name Posilac (originally Monsanto, later Elanco).

What is Mineral Oil?

Mineral oil (E905) is a refined petroleum product used as a food-grade lubricant, coating agent, and glazing agent in food processing and production. Food-grade mineral oil is a highly refined grade of petroleum distillate with specifications limiting impurities. It differs from pharmaceutical-grade (Vaseline) and cosmetic-grade mineral oils in refinement level.

Documented risks

Recombinant Bovine Growth Hormone: The central human health concern is that rBGH treatment significantly elevates insulin-like growth factor 1 (IGF-1) levels in treated cows' milk. IGF-1 is a naturally occurring growth hormone that promotes cell growth and division. Multiple epidemiological studies have associated elevated blood IGF-1 levels with increased cancer risk in humans. A 1998 study in The Lancet (Hankinson et al.) found that women with the highest IGF-1 blood levels had approximately 7 times the breast cancer risk compared to those with the lowest levels. A 2004 meta-analysis in JNCI (the Journal of the National Cancer Institute) confirmed significant associations between high IGF-1 levels and breast, prostate, and colorectal cancer risk. The mechanistic question is whether consuming rBGH-treated milk raises blood IGF-1 levels in humans. The FDA and WHO/FAO Codex Alimentarius concluded that IGF-1 in milk is a protein largely digested in the GI tract before absorption. Canadian regulatory researchers challenged this, arguing that pasteurization reduces proteases that would otherwise break down IGF-1, potentially allowing more intact IGF-1 to survive digestion. The Codex Alimentarius Commission made history in 1999 by declining to endorse rBST safety maximum residue limits — a split vote (33 in favor of the MRL, 29 against, with abstentions) demonstrating fundamental international disagreement. This is one of very few cases where Codex failed to establish a safety standard. Animal welfare is a second major concern: Health Canada's comprehensive 1999 review found that rBGH-treated cows had 25% higher rates of clinical mastitis, 50% higher lameness risk, increased reproductive problems, and shortened productive lifespans, requiring substantially more antibiotic treatment — an antibiotic resistance concern. Canada rejected rBGH approval in 1999 after its scientific review; the EU banned it in 1999.

Mineral Oil: EFSA has raised significant concerns about mineral oil hydrocarbons (MOH) contamination in food through two pathways: (1) deliberate food-grade mineral oil use in coatings and processing, and (2) migration from recycled paper and cardboard food packaging into food. MOH comprises two types: mineral oil saturated hydrocarbons (MOSH), which accumulate in human adipose tissue, liver, and spleen, and mineral oil aromatic hydrocarbons (MOAH), which include polycyclic aromatic hydrocarbons (PAHs) that are potentially carcinogenic. A 2011 Swiss study found mineral oil hydrocarbons in human liver and spleen samples from autopsy, demonstrating real bioaccumulation. EFSA's 2023 preliminary opinion identified MOAH contamination in food as a safety concern that cannot be dismissed, recommending ALARA (as low as reasonably achievable) minimization. Untreated and mildly treated mineral oils are IARC Group 1 human carcinogens for occupational inhalation. Highly refined food-grade mineral oil (E905) is not classified as a direct carcinogen, but MOAH contamination in even food-grade mineral oil is an ongoing concern.